METEROderna, who is rushing to develop a vaccine for Covid-19, lost a key patent decision Thursday, one that could delay the company’s progress or force it to deliver a profit cut.
The United States Patent and Trademark Office denied Moderna’s claim that a patent from a rival company was invalid. The patent, which covers the technology used to administer messenger RNA treatments, is owned by the Canadian firm Arbutus.
Unlock this item by subscribing to STAT Plus and enjoy your first 30 days free!
START
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharmacy, policy and life science analysis and coverage. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific breakthroughs, and clinical trial results and healthcare disruption in Silicon Valley and beyond.
What is included?
- Daily reports and analysis.
- The industry’s most comprehensive coverage of a powerful team of reporters
- Subscribers only newsletters
- Daily newsletters to inform you about the industry’s most important news of the day.
- STAT + conversations
- Weekly opportunities to network with our industry leading reporters and experts in live video conversations
- Industry exclusive events.
- Premium access to network events only for subscribers across the country
- The best reporters in the industry.
- The most reliable and well connected newsroom in the healthcare industry.
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.
